Sanofi India Q2: PAT up 20%, diabetes portfolio grows 14%, board reconstituted

Exceptional ItemEbitda Margin ExpansionResults View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹3395.00

prior close

₹3411.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-3.5% vs market

Pharmaceuticals peers, median of 165sector-0.0%-2.2% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-2.5

15m

-2.1

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+1.3-3.5-0.0-2.2

Next day

-1.2+1.6-2.8+0.2-1.4

-1.3+1.7-3.0+0.4-1.7

-1.9+1.6-3.5+1.1-3.0

-2.8+1.5-4.2+1.2-4.0

-4.8+1.8-6.6+1.0-5.8

-4.7+2.1-6.8+0.5-5.2

15d

-6.1+3.2-9.2+0.2-6.2

-8.1+3.7-11.8+1.7-9.8

-11.0+1.1-12.2+1.2-12.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India reported Q2 2026 revenue of Rs 437.7 crore, up 8% YoY. PAT rose to Rs 83.5 crore from Rs 69.5 crore, a 20% jump. EPS at Rs 36.26 vs Rs 30.18. Diabetes portfolio grew 14% for the second straight quarter. PBT before exceptional items up 19% to Rs 112 crore. H1 revenue at Rs 910 crore was slightly lower than Rs 942 crore YoY. Board reconstituted committees effective Oct 1, 2026. CFO Rachid Ayari to step down Sept 30, 2026. Auditor review report is clean.

Likely market impact

Strong quarter with double-digit diabetes growth and 20% PAT rise. CFO exit and committee reshuffle are key management changes to watch.